ORAGENICS INC
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
OGEN$0.34-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Cash flows from operating activities: | |||
| Net loss | $(10,567,918) | $(20,655,737) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Write off of in process research and development (IPR&D) | - | 10,273,506 | |
| Depreciation and amortization | - | 27,391 | |
| Loss on sale of fixed assets, net | - | 29,956 | |
| Stock-based compensation expense | 516,049 | 1,016,828 | |
| Changes in operating assets and liabilities: | |||
| Operating lease right-of-use assets | 9,811 | 337,629 | |
| Prepaid expenses and other current assets | 483,537 | 2,000,824 | |
| Prepaid research and development expense | 1,090,750 | - | |
| Operating lease liabilities | (9,811) | (347,075) | |
| Accounts payable and accrued expenses | (119,800) | 25,798 | |
| Net cash used in operating activities | (8,597,382) | (7,290,880) | |
| Cash flows from investing activities: | |||
| Proceeds from sale of property and equipment | - | 63,716 | |
| Cash paid for IPR&D | - | (1,000,000) | |
| Net cash used in investing activities | - | (936,284) | |
| Cash flows from financing activities: | |||
| Payments on short-term notes payable | (693,109) | (566,046) | |
| Proceeds from issuance of common stock for private placement | 6,671,830 | 849,926 | |
| Net cash provided by financing activities | 5,978,721 | 283,880 | |
| Net decrease in cash and cash equivalents | (2,618,661) | (7,943,284) | |
| Cash and cash equivalents at beginning of year | 3,483,501 | 11,426,785 | |
| Cash and cash equivalents at end of year | $864,840 | $3,483,501 | |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | $29,828 | $30,591 | |
| Non-cash investing and financing activities: | |||
| Borrowings under short term notes payable for prepaid insurance | $708,934 | $611,109 | |
| Issuance of Series F Preferred stock for IPR&D | $ | - | $8,947,834 |
| Value of Series A preferred stock converted into common stock | $562,243 | $— | |
| Value of Series B preferred stock converted into common stock | $1,030,480 | $— | |
| Par Value of common stock issued in connection with Series A Preferred Stock Conversion | $9 | $— | |
| Par Value of common stock issued in connection with Series B Preferred Stock Conversion | $13 | $— | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.